Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).

NCT Number	NCT07291102
Lead Sponsor	Nationwide Children's Hospital Collaborators: German Society of Paediatric Oncology and Hematology (GPOH gGmbH), Children's of Alabama
Conditions	Medulloblastoma
Enrollment	96 participants
Start Date	2026-07-01
Primary Completion	2034-10 (estimated)
Study Completion	2038-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-18